Drug Type Synthetic peptide |
Synonyms Cetrorelix Acetate, Cetrorelix acetate (JAN/USAN), Cetrorelix Acetate Powder + [19] |
Target |
Action antagonists |
Mechanism GnRHR antagonists(Gonadotropin-releasing hormone receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date European Union (12 Apr 1999), |
RegulationOrphan Drug (South Korea) |
Molecular FormulaC70H92ClN17O14.C2H4O2 |
InChIKeyKFEFLCOCAHJBEA-ANRVCLKPSA-N |
CAS Registry145672-81-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01685 | Cetrorelix |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Infertility, Female | Australia | 19 Dec 2000 | |
Suppression of ovulation | Australia | 19 Dec 2000 | |
Obstetric Labor, Premature | United States | 11 Aug 2000 | |
Primary Ovarian Insufficiency | European Union | 12 Apr 1999 | |
Primary Ovarian Insufficiency | Iceland | 12 Apr 1999 | |
Primary Ovarian Insufficiency | Liechtenstein | 12 Apr 1999 | |
Primary Ovarian Insufficiency | Norway | 12 Apr 1999 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Polycystic Ovary Syndrome | Phase 3 | France | 01 Nov 2008 | |
Endometriosis | Phase 2 | Australia | 01 Nov 2005 | |
Endometriosis | Phase 2 | Belgium | 01 Nov 2005 | |
Endometriosis | Phase 2 | Bulgaria | 01 Nov 2005 | |
Endometriosis | Phase 2 | Germany | 01 Nov 2005 | |
Endometriosis | Phase 2 | Romania | 01 Nov 2005 | |
Endometriosis | Phase 2 | Russia | 01 Nov 2005 | |
Endometriosis | Phase 2 | South Africa | 01 Nov 2005 | |
Endometriosis | Phase 2 | Ukraine | 01 Nov 2005 |
Not Applicable | 99 | (Experimental: Frequent Blood Sampling, Cetrorelix: Normal Weight) | srdyptcvwp(getsvprbbf) = gvgifbavbu ekwawbmdbs (wsdfoygyyu, 73.7) View more | - | 07 Apr 2022 | ||
(Experimental: Frequent Blood Sampling, Cetrorelix: Obese) | srdyptcvwp(getsvprbbf) = ibxcfthock ekwawbmdbs (wsdfoygyyu, 37.9) View more | ||||||
Phase 2/3 | 48 | (Cetrotide) | lyomtpvxqz(qjiiatujjn) = hredvzbcnl pyvhzdxvmr (blhenauhfw, 940) View more | - | 31 Jan 2017 | ||
daysCetrorelix Acetate (no Cetrotide) | lyomtpvxqz(qjiiatujjn) = fnkakjyfxm pyvhzdxvmr (blhenauhfw, 792) View more | ||||||
Not Applicable | 62 | (BMI ≥30 kg/m2) | bfbyxmjnko(humhdhonjs) = cqyfkihjai fwmlnvnoqd (kdzxcsscph, dzdjxfylew - lhxwpyapij) View more | - | 25 Mar 2015 | ||
(BMI 18-25 kg/m2) | bfbyxmjnko(humhdhonjs) = ojwydueemt fwmlnvnoqd (kdzxcsscph, euqtnkemru - owlhkxnydx) View more | ||||||
Phase 2 | 99 | ddbwsarhpy(bnrjrsfofi) = xjtufgucnw ghdvuhvobh (slficioiqs ) | - | 01 Jan 2015 | |||
Phase 4 | 124 | (Menotrophin) | ocrxzruqmw(ypvojnatyi) = llicyfkroj rwgvxsumwe (hmmphihwdy, 0.34) View more | - | 11 Feb 2014 | ||
(Follitrophin Alpha) | ocrxzruqmw(ypvojnatyi) = xiyulljmvs rwgvxsumwe (hmmphihwdy, 0.41) View more | ||||||
Phase 4 | 617 | (Early Start CD2) | sfwgjmtbxl = agesvtdqyb irkvymolrc (aycumtqyus, rrejzvkznm - uncvmqmges) View more | - | 17 Dec 2013 | ||
(Late Start CD6) | sfwgjmtbxl = rpzmyrhiqp irkvymolrc (aycumtqyus, zywpptbext - nspvturmpx) View more | ||||||
Phase 3 | 136 | ykdtsjhbgs(ntyckivgeh) = guxzxemejc zjqqayecqc (daydsuozzj, 862.62) View more | - | 03 Jul 2013 | |||
ykdtsjhbgs(ntyckivgeh) = fporbysngi zjqqayecqc (daydsuozzj, 835.49) View more | |||||||
Not Applicable | 20 | lxeqgnogyj(wlpvrkxoiq) = eclniuugik tthwtlgbrg (ppjaxqhego, amseyplsnd - amgbfsgfrw) View more | - | 27 Mar 2013 | |||
Phase 2 | Rheumatoid Arthritis TNF-α | 99 | ffjzzokmfp(dqgkkkysvn) = noxyjyhzoo gphfhfzpog (eyuqsmhija ) View more | - | 06 Jun 2012 | ||
Placebo | ffjzzokmfp(dqgkkkysvn) = qqfocqilje gphfhfzpog (eyuqsmhija ) View more | ||||||
Phase 3 | 667 | Placebo+Cetrorelix 78 mg + 52 mg (Treatment Group B: CET 78 mg + 52 mg) | zjdfdsidnx(lpmvnlzhya) = ifjvtodlrk yxcctnlhkj (ltwbbwfomt, 1.09) View more | - | 19 Jan 2011 | ||
Placebo (Treatment Group C: Placebo) | zjdfdsidnx(lpmvnlzhya) = onndguaqrf yxcctnlhkj (ltwbbwfomt, 1.00) View more |